GlobeNewswire·Aug 25, 2026, 8:00 AM ET

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Septerna, Inc. appointed Rajiv Patni, M.D. as Chief Medical Officer on August 25, 2026.
Dr. Patni brings over 25 years of experience leading research, development, regulatory, and medical affairs in the biopharmaceutical sector.
He previously served as Chief Executive Officer at Judo Bio and Chief Research and Development Officer at Reata Pharmaceuticals.
His career includes roles as Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals, and Actelion Pharmaceuticals.
Earlier roles included leading development teams at Pfizer and Roche Pharmaceuticals.
Dr. Patni contributed to programs resulting in 10 regulatory agency approvals or label expansions in the US, Europe, and other markets.
He currently serves as a director of BioXcel Therapeutics.
Dr. Patni holds an M.D. from the Icahn School of Medicine at Mt. Sinai.
He completed internal medicine residency and cardiology fellowship at the Albert Einstein College of Medicine.
Septerna is a clinical-stage biotechnology company focused on GPCR drug discovery using its proprietary Native Complex Platform.
The company is advancing oral small molecule drug candidates in endocrinology, immunology, inflammation, metabolic diseases, and other therapeutic areas.